In every dimension of our business, we’re elevating our commitment to deliver essential innovations that enrich people’s lives, enable sustainable development and foster human potential for generations to come.

From smarter homes to more efficient cars, from better ways of digitally connecting to new tools that enable active and healthy lifestyles...in all these areas and many more, we’re working with customers to transform their ideas into real world answers that help humanity thrive.
Our businesses
Market-leading, innovation-led growth segments

**FY2018**(1)

**Electronics & Imaging**
Sales: $4.7B
Adjusted Op EBITDA Margin: 31%(2)

**Nutrition & Biosciences**
Sales: $6.8B
Adjusted Op EBITDA Margin: 24%

**Safety & Construction**
Sales: $5.5B
Adjusted Op EBITDA Margin: 24%

**Transportation & Advanced Polymers**
Sales: $5.6B
Adjusted Op EBITDA Margin: 29%

DuPont – 5% organic revenue(3) growth & 12% adjusted operating EBITDA(3) growth

---

(1) On segment basis as part of DowDuPont and prior to realignment of certain businesses to Non-Core segment
(2) Adjusted operating EBITDA margin excludes equity affiliate income of $412 million
(3) Results for Specialty Products division of DowDuPont. Refer to definition of key terms in appendix
With the new segment we aim to:

- Refine and align our portfolio with attractive, high-growth, high-return market opportunities
- Provide focused resources to define the best, tailored value creation strategies
- Maximize long-term sustainable growth and returns
- Bring more transparency to the performance of our core segments

Businesses within new Non-Core segment

- Tedlar® PVF materials • Solamet® PV pastes • advanced materials pastes • solar silicones • trichlorosilane (TCS) • Hemlock Semiconductor JV
- Sulfuric acid • alkylation • scrubbing • IsoTherming® hydro processing technology
- Sorona® eco-efficient performance fiber for carpet and apparel applications • bio-PDO from JV with Tate & Lyle • strong pipeline of other pre-commercial biotech programs
- Mylar® and Melinex® PET films • Teonex® PEN films
- Operational risk management • operational excellence • learning and development solutions

~$2B
FY 2018 net sales

~23%(1)
FY 2018 Op. EBITDA margin

(1) 2018 operating EBITDA margin on as reported segment basis as part of DowDuPont. Amount excludes Hemlock Semiconductor JV and DuPont Teijin Films JV equity earnings
Strong focus on returns

Disciplined capital allocation to deliver consistent top-tier returns

~4% annual R&D investment target as % of sales

~4-5% annual capex target as % of sales

~100 bps annual ROIC improvement target

>90% free cashflow conversion target
Well positioned to benefit from global macro trends

Health & Wellness

Digital Revolution & Connectivity

Advanced Mobility

Medical & Pharma

Personal Protection

Sustainability
2019 priorities focused on shareholder value creation

Priorities

- Drive top line growth through innovation and pricing discipline
- Expand margins through strong productivity focus and synergy capture
- Continue to execute portfolio actions and upgrades
- Enable strong cash generation through earnings growth and working capital productivity
- Continue to improve ROIC through effective capital allocation and R&D spend

Progress

- 3% price growth in Q1 vs prior year
- ~$135 million incremental synergies delivered in Q1 vs prior year
- Creating non-core segment to capture businesses to be divested
- Q1 operating EBITDA flat vs prior year. Delivered 3% growth excluding currency
- Tying executive compensation to ROIC
The new DuPont: broad end-market exposure

~20% net sales into markets with short-term destocking

Majority of end-markets experiencing growth rates consistent with our mid-term expectations

Automotive
~15% of Net Sales

Medical & Pharmaceutical

Industrial & Personal Protection

Smartphone
~5% of Net Sales

Food & Beverage

Semiconductor & Other Digital

Health & Wellness

Construction & Infrastructure

2019 guidance in-line with current macro trends
Balanced financial policy

- **Strong balance sheet**: Committed to a strong investment grade credit profile
- **Internal investment**: Disciplined capital allocation to support product and market innovation
- **Dividends**: Stable and growing dividend; targeting ~30-40% payout of adjusted net income
- **Portfolio management and acquisitions**: Divestments of about 15% of revenue and acquisitions that fit core competencies and meet return criteria
- **Share repurchase**: Return excess cash to shareholders through share buybacks

Intend to announce $2B share buyback plan at separation; purchases to commence during 2019
Re-iterate 2Q and FY 2019 guidance

<table>
<thead>
<tr>
<th></th>
<th>Net Sales</th>
<th>Op. EBITDA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>As reported:</td>
<td>As reported:</td>
</tr>
<tr>
<td>2Q 2019</td>
<td>Down mid-single digits</td>
<td>Down mid-single digits</td>
</tr>
<tr>
<td></td>
<td><strong>Organic</strong>(^{(1)}):</td>
<td><strong>Adjusted</strong>(^{(2)}):</td>
</tr>
<tr>
<td></td>
<td>Down low-single digits</td>
<td>Down low-single digits</td>
</tr>
<tr>
<td>Full-Year 2019</td>
<td>As reported:</td>
<td>As reported:</td>
</tr>
<tr>
<td></td>
<td>Flat</td>
<td>Slightly down</td>
</tr>
<tr>
<td></td>
<td><strong>Organic</strong>(^{(1)}):</td>
<td><strong>Adjusted</strong>(^{(2)}(3)):</td>
</tr>
<tr>
<td></td>
<td>Up 2-3%</td>
<td>Up 3-5%</td>
</tr>
</tbody>
</table>

\(^{(1)}\) Organic sales growth – defined as price and volume, excluding currency and portfolio impacts
\(^{(2)}\) Operating EBITDA on an adjusted basis excludes impacts of currency and portfolio
\(^{(3)}\) Full-year operating EBITDA on an adjusted basis excludes impact from the anticipated decline in equity affiliate income of $200 - $225 million and lower non-operating pension / OPEB benefits
Key takeaways

- We have leading positions in attractive growth markets
- We are committed to top line growth and above-market earnings improvement
- We have a plan to increase ROIC and drive value creation
- We will maximize shareholder value through prudent portfolio actions

Focused on consistently delivering shareholder value
Appendix
<table>
<thead>
<tr>
<th>Division</th>
<th>1Q17</th>
<th>2Q17</th>
<th>3Q17</th>
<th>4Q17</th>
<th>2017</th>
<th>1Q18</th>
<th>2Q18</th>
<th>3Q18</th>
<th>4Q18</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>In millions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>As Reported</td>
</tr>
<tr>
<td><strong>Operating EBITDA</strong></td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>As Reported</td>
<td>Pro Forma</td>
<td>As Reported</td>
<td>As Reported</td>
<td>As Reported</td>
<td>As Reported</td>
</tr>
<tr>
<td><strong>Electronics &amp; Imaging</strong></td>
<td>$407</td>
<td>$441</td>
<td>$411</td>
<td>$581</td>
<td>$1,840</td>
<td>$398</td>
<td>$407</td>
<td>$412</td>
<td>$685</td>
<td>$1,902</td>
</tr>
<tr>
<td>Adjusted operating EBITDA</td>
<td>414</td>
<td>448</td>
<td>413</td>
<td>572</td>
<td>1,846</td>
<td>387</td>
<td>396</td>
<td>401</td>
<td>675</td>
<td>1,861</td>
</tr>
<tr>
<td><strong>Nutrition &amp; Biosciences</strong></td>
<td>$315</td>
<td>$317</td>
<td>$312</td>
<td>$352</td>
<td>$1,296</td>
<td>$418</td>
<td>$433</td>
<td>$414</td>
<td>$367</td>
<td>$1,632</td>
</tr>
<tr>
<td>Adjusted operating EBITDA</td>
<td>323</td>
<td>325</td>
<td>315</td>
<td>344</td>
<td>1,308</td>
<td>411</td>
<td>426</td>
<td>407</td>
<td>357</td>
<td>1,601</td>
</tr>
<tr>
<td><strong>Transportation &amp; Advanced Polymers</strong></td>
<td>$321</td>
<td>$308</td>
<td>$325</td>
<td>$365</td>
<td>$1,319</td>
<td>$437</td>
<td>$446</td>
<td>$430</td>
<td>$389</td>
<td>$1,702</td>
</tr>
<tr>
<td>Adjusted operating EBITDA</td>
<td>342</td>
<td>329</td>
<td>333</td>
<td>345</td>
<td>1,348</td>
<td>418</td>
<td>427</td>
<td>411</td>
<td>369</td>
<td>1,625</td>
</tr>
<tr>
<td><strong>Safety &amp; Construction</strong></td>
<td>$292</td>
<td>$263</td>
<td>$353</td>
<td>$286</td>
<td>$1,194</td>
<td>$354</td>
<td>$341</td>
<td>$389</td>
<td>$343</td>
<td>$1,427</td>
</tr>
<tr>
<td>Adjusted operating EBITDA</td>
<td>319</td>
<td>290</td>
<td>363</td>
<td>259</td>
<td>1,232</td>
<td>329</td>
<td>316</td>
<td>364</td>
<td>317</td>
<td>1,326</td>
</tr>
<tr>
<td><strong>Specialty Products Division of DowDuPont</strong></td>
<td>$1,335</td>
<td>$1,329</td>
<td>$1,401</td>
<td>$1,584</td>
<td>$5,649</td>
<td>$1,607</td>
<td>$1,627</td>
<td>$1,645</td>
<td>$1,784</td>
<td>$6,663</td>
</tr>
<tr>
<td>Adjusted operating EBITDA</td>
<td>1,398</td>
<td>1,392</td>
<td>1,423</td>
<td>1,520</td>
<td>5,753</td>
<td>1,545</td>
<td>1,565</td>
<td>1,583</td>
<td>1,719</td>
<td>6,413</td>
</tr>
</tbody>
</table>
## Non-GAAP Reconciliation

### Electronics & Imaging

<table>
<thead>
<tr>
<th></th>
<th>1Q17</th>
<th>2Q17</th>
<th>3Q17</th>
<th>4Q17</th>
<th>2017</th>
<th>1Q18</th>
<th>2Q18</th>
<th>3Q18</th>
<th>4Q18</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operating EBITDA Margins</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
</tr>
<tr>
<td>Remove: Non-operating pension &amp; OPEB (cost) / benefit</td>
<td>35.0%</td>
<td>36.1%</td>
<td>34.3%</td>
<td>48.7%</td>
<td>38.5%</td>
<td>34.5%</td>
<td>33.8%</td>
<td>34.5%</td>
<td>58.6%</td>
<td>40.3%</td>
</tr>
<tr>
<td>Adjusted operating EBITDA Margins</td>
<td>35.5%</td>
<td>36.7%</td>
<td>34.5%</td>
<td>48.0%</td>
<td>38.7%</td>
<td>33.6%</td>
<td>33.0%</td>
<td>33.6%</td>
<td>57.8%</td>
<td>39.4%</td>
</tr>
</tbody>
</table>

### Nutrition & Biosciences

<table>
<thead>
<tr>
<th></th>
<th>1Q17</th>
<th>2Q17</th>
<th>3Q17</th>
<th>4Q17</th>
<th>2017</th>
<th>1Q18</th>
<th>2Q18</th>
<th>3Q18</th>
<th>4Q18</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operating EBITDA Margins</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
</tr>
<tr>
<td>Remove: Non-operating pension &amp; OPEB (cost) / benefit</td>
<td>22.2%</td>
<td>21.3%</td>
<td>21.3%</td>
<td>22.3%</td>
<td>21.8%</td>
<td>24.3%</td>
<td>24.4%</td>
<td>24.7%</td>
<td>22.5%</td>
<td>24.0%</td>
</tr>
<tr>
<td>Adjusted operating EBITDA Margins</td>
<td>22.8%</td>
<td>21.9%</td>
<td>21.5%</td>
<td>21.7%</td>
<td>22.0%</td>
<td>23.9%</td>
<td>24.0%</td>
<td>24.3%</td>
<td>21.9%</td>
<td>23.5%</td>
</tr>
</tbody>
</table>

### Transportation & Advanced Polymers

<table>
<thead>
<tr>
<th></th>
<th>1Q17</th>
<th>2Q17</th>
<th>3Q17</th>
<th>4Q17</th>
<th>2017</th>
<th>1Q18</th>
<th>2Q18</th>
<th>3Q18</th>
<th>4Q18</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operating EBITDA Margins</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
</tr>
<tr>
<td>Remove: Non-operating pension &amp; OPEB (cost) / benefit</td>
<td>25.7%</td>
<td>24.0%</td>
<td>25.0%</td>
<td>28.1%</td>
<td>25.7%</td>
<td>30.7%</td>
<td>30.4%</td>
<td>30.5%</td>
<td>29.5%</td>
<td>30.3%</td>
</tr>
<tr>
<td>Adjusted operating EBITDA Margins</td>
<td>27.3%</td>
<td>25.6%</td>
<td>25.6%</td>
<td>26.6%</td>
<td>26.3%</td>
<td>29.3%</td>
<td>29.1%</td>
<td>29.2%</td>
<td>28.0%</td>
<td>28.9%</td>
</tr>
</tbody>
</table>

### Safety & Construction

<table>
<thead>
<tr>
<th></th>
<th>1Q17</th>
<th>2Q17</th>
<th>3Q17</th>
<th>4Q17</th>
<th>2017</th>
<th>1Q18</th>
<th>2Q18</th>
<th>3Q18</th>
<th>4Q18</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operating EBITDA Margins</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
</tr>
<tr>
<td>Remove: Non-operating pension &amp; OPEB (cost) / benefit</td>
<td>24.1%</td>
<td>19.8%</td>
<td>26.9%</td>
<td>22.2%</td>
<td>23.2%</td>
<td>27.3%</td>
<td>24.2%</td>
<td>27.7%</td>
<td>25.6%</td>
<td>26.2%</td>
</tr>
<tr>
<td>Adjusted operating EBITDA Margins</td>
<td>26.3%</td>
<td>21.8%</td>
<td>27.7%</td>
<td>20.1%</td>
<td>24.0%</td>
<td>25.3%</td>
<td>22.4%</td>
<td>26.0%</td>
<td>23.6%</td>
<td>24.3%</td>
</tr>
</tbody>
</table>

### Specialty Products Division of DowDuPont

<table>
<thead>
<tr>
<th></th>
<th>1Q17</th>
<th>2Q17</th>
<th>3Q17</th>
<th>4Q17</th>
<th>2017</th>
<th>1Q18</th>
<th>2Q18</th>
<th>3Q18</th>
<th>4Q18</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operating EBITDA Margins</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
<td>Pro Forma</td>
</tr>
<tr>
<td>Remove: Non-operating pension &amp; OPEB (cost) / benefit</td>
<td>26.5%</td>
<td>25.0%</td>
<td>26.6%</td>
<td>29.5%</td>
<td>26.9%</td>
<td>28.7%</td>
<td>27.8%</td>
<td>28.9%</td>
<td>32.7%</td>
<td>29.5%</td>
</tr>
<tr>
<td>Adjusted operating EBITDA Margins</td>
<td>27.7%</td>
<td>26.2%</td>
<td>27.0%</td>
<td>28.4%</td>
<td>27.3%</td>
<td>27.6%</td>
<td>26.7%</td>
<td>27.9%</td>
<td>31.5%</td>
<td>28.4%</td>
</tr>
</tbody>
</table>
Key terms

**Organic revenue** includes price and volume and excludes impacts of currency and portfolio

**Adjusted Operating EBITDA** is defined as operating EBITDA excluding non-operating pension/OPEB costs and credits

**Adjusted Operating EBITDA Margin** reflects Adjusted Operating EBITDA divided by net sales

---

Note – where provided for the new DuPont, the above metrics equal the aggregation of results for the Electronics & Imaging, Nutrition & Biosciences, Transportation & Advanced Polymers and Safety & Construction segments of DowDuPont
Safe Harbor Statement

Cautionary Statement About Forward-Looking Statements

This communication contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "target," and similar expressions and variations or negatives of these words.

Forward-looking statements by their nature address matters that are, to varying degrees, uncertain, including statements about the Corteva Distribution. Forward-looking statements, including those related to DowDuPont's ability to complete, or to make any filing or take any other action required to be taken to complete, the Corteva Distribution, are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. Forward-looking statements also involve risks and uncertainties, many of which are beyond DowDuPont's control. Some of the important factors that could cause DowDuPont's actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to: (i) ability and costs to achieve all the expected benefits from the Corteva Distribution and the April 1, 2019 distribution by DowDuPont of all of the shares of common stock of Dow Inc. on a pro rata basis to the holders of DowDuPont common stock (the "Dow Distribution"); (ii) restrictions under intellectual property cross license agreements entered into or to be entered into in connection with the Corteva Distribution and the Dow Distribution; (iii) ability to receive third-party consents required under the Separation Agreement entered into in connection with the Corteva Distribution and the Dow Distribution; (iv) non-compete restrictions under the Separation Agreement entered into in connection with the Corteva Distribution and the Dow Distribution; (v) the incurrence of significant costs in connection with the Corteva Distribution and the Dow Distribution, including increased costs from supply, service and other arrangements that, prior to the Dow Distribution, were between entities under the common control of DowDuPont; (vi) risks outside the control of DowDuPont which could impact the decision of the DowDuPont Board of Directors to proceed with the Corteva Distribution, including, among others, global economic conditions, instability in credit markets, declining consumer and business confidence, fluctuating commodity prices and interest rates, volatile foreign currency exchange rates, tax considerations, other challenges that could affect the global economy, specific market conditions in one or more of the industries of the businesses proposed to be separated, and changes in the regulatory or legal environment and the requirement to redeem $12.7 billion of DowDuPont notes if the Corteva Distribution is abandoned or delayed beyond May 1, 2020; (vii) potential liability arising from fraudulent conveyance and similar laws in connection with the Corteva Distribution and/or the Dow Distribution; (viii) disruptions or business uncertainty, including from the Corteva Distribution, could adversely impact DowDuPont's business or financial performance and its ability to retain and hire key personnel; (ix) uncertainty as to the long-term value of DowDuPont common stock; (x) potential inability to access the capital markets; (xi) uncertainties related to share buybacks including board approval and costs, time and ability to complete; and (xii) risks to DowDuPont's business, operations and results of operations from: the availability of and fluctuations in the cost of feedstocks and energy; balance of supply and demand and the impact of balance on prices; failure to develop and market new products and optimally manage product life cycles; ability, cost and impact on business operations, including the supply chain, of responding to changes in market acceptance, rules, regulations and policies and failure to respond to such changes; outcome of significant litigation, environmental matters and other commitments and contingencies; failure to appropriately manage process safety and product stewardship issues; global economic and capital market conditions, including the continued availability of capital and financing, as well as inflation, interest and currency exchange rates; changes in political conditions, including trade disputes and retaliatory actions; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, natural disasters and weather events and patterns which could result in a significant operational event for DowDuPont, adversely impact demand or production; ability to discover, develop and protect new technologies and to protect and enforce DowDuPont's intellectual property rights; failure to effectively manage acquisitions, divestitures, alliances, joint ventures and other portfolio changes; unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as management's response to any of the aforementioned factors. These risks are and will be more fully discussed in DowDuPont's current, quarterly and annual reports and other filings made with the U.S. Securities and Exchange Commission, in each case, as may be amended from time to time in future filings with the SEC. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DowDuPont's or Corteva's consolidated financial condition, results of operations, credit rating or liquidity. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. DowDuPont assumes no obligation to publicly provide revisions or updates to any forward-looking statements whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements is included in the section titled "Risk Factors" (Part I, Item 1A) of DowDuPont's 2018 Annual Report on Form 10-K as modified by DowDuPont's 2019 quarterly reports on Form 10-Q and current reports on Form 8-K.
Safe Harbor Statement

Cautionary Statement About Forward-Looking Statements, continued

Segment Information: DowDuPont’s measure of profit/loss for segment reporting purposes is Operating EBITDA for the twelve months ended December 31, 2018 and pro forma Operating EBITDA for the twelve months ended December 31, 2017 and 2016 as this is the manner in which DowDuPont’s chief operating decision maker (“CODM”) assesses performance and allocates resources. DowDuPont defines Operating EBITDA as earnings (i.e., “Income from continuing operations before income taxes”) before interest, depreciation, amortization and foreign exchange gains (losses), excluding the impact of significant items. Pro forma Operating EBITDA is defined as pro forma earnings (i.e. pro forma "Income from continuing operations before income taxes") before interest, depreciation, amortization and foreign exchange gains (losses), excluding the impact of adjusted significant items. Reconciliations of these measures are provided in DowDuPont’s’s most recent Annual Report on Form 10-K as well as on DowDuPont’s website under the Investors section. DowDuPont utilizes pro forma net sales for 2017 and 2016 as it is included in management’s measure of segment performance and is regularly reviewed by the CODM.

Non-GAAP Information: This presentation includes information that differs from DowDuPont’s measure of profit/loss for segment reporting purposes, does not conform to U.S. GAAP and are considered non-GAAP measures. These measures include adjusted Operating EBITDA and pro forma adjusted Operating EBITDA, both adjusted by removing expense/benefits associated with non-operating pension and other postemployment benefits (OPEBs), as well as adjusted Operating EBITDA margin and pro forma adjusted Operating EBITDA margin. Reconciliations for these non-GAAP measures to GAAP measurements are included in this presentation. Other metrics presented utilizing these measures include adjusted Operating EBITDA growth and adjusted Operating EBITDA leverage, as defined herein. Management considers these measures internally for planning, forecasting and evaluating the performance of our segments. We believe that these non-GAAP measures best reflect the ongoing performance of DuPont during the periods presented and provide more relevant and meaningful information to investors as they provide insight with respect to ongoing operating results of the new DuPont and a more useful comparison of year-over-year results. These non-GAAP measures supplement our U.S. GAAP disclosures and should not be viewed as an alternative to U.S. GAAP measures of performance. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies.

Organic Sales: Net Sales on an organic basis excludes impacts of currency and portfolio.

Divisional Information: Discussion of results on a divisional level, including but not limited to, DuPont net sales, operating EBITDA and operating EBITDA margin, including on a pro forma basis, and adjusted Operating EBITDA and adjusted Operating EBITDA margin, including on a pro forma basis, and price/volume metrics is based on the combined and separate results of and estimates for DowDuPont’s Electronics & Imaging, Nutrition & Biosciences, Transportation & Advanced Polymers, and Safety & Construction segments. This information is presented in this manner for informational purposes only and should not be viewed as an indication of DuPont’s current or future operating results on a stand-alone basis assuming completion of the intended business separations.

Unaudited Pro Forma Financial Information: The unaudited pro forma financial information has been developed by applying adjustments to the historical consolidated financial statements and accompanying notes of both Historical Dow and Historical DuPont and has been prepared to illustrate the effects of the Merger, assuming the Merger had been consummated on January 1, 2016. The results for the twelve months ended December 31, 2018 are presented on a U.S. GAAP basis. For all other prior periods presented, unless otherwise stated, adjustments have been made for (1) the purchase accounting impact, (2) accounting policy alignment, (3) eliminate the effect of events that are directly attributable to the Merger Agreement (e.g., one-time transaction costs), (4) eliminate the impact of transactions between Historical Dow and Historical DuPont, and (5) eliminate the effect of consummated divestitures agreed to with certain regulatory agencies as a condition of approval for the Merger. The unaudited pro forma financial information was based on and should be read in conjunction with the separate historical financial statements and accompanying notes contained in each of the Historical Dow and Historical DuPont Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K for the applicable periods. The pro forma financial statements were prepared in accordance with Article 11 of Regulation S-X. The unaudited pro forma adjustments reflected herein were based upon available information and certain assumptions that DowDuPont believes are reasonable under the circumstances. The unaudited pro forma financial information has been presented for informational purposes only and is not necessarily indicative of what DowDuPont’s results of operations actually would have been had the Merger been completed as of January 1, 2016, nor is it indicative of the future operating results of DowDuPont. The unaudited pro forma financial information does not reflect any cost or growth synergies that DowDuPont may achieve as a result of the Merger, future costs to combine the operations of Historical Dow and Historical DuPont or the costs necessary to achieve any cost or growth synergies. For further information on the unaudited pro forma financial information, please refer to the Company’s Current Report on Form 8-K dated October 26, 2017.

Full Year 2019 Guidance: Full year 2019 guidance and estimates, including information denoted “2019E”, for Net Sales and Adjusted Operating EBITDA (collectively, the "FY2019 Guidance") are based on forward-looking information provided in connection with DowDuPont’s fourth quarter 2018 earnings announcement (“DowDuPont’s FY2019 Guidance”) for results of operations for DowDuPont’s Specialty Products Division and the segments that comprise it: Electronics & Imaging, Nutrition & Biosciences, Transportation & Advanced Polymers, and Safety & Construction, and the relative contribution of each such segment to divisional results of operations. FY2019 Guidance are not intended to and should not be interpreted as updating DowDuPont’s Guidance for 2019.